Nuvectis Pharma (NVCT) Treasury Shares (2021 - 2026)

Nuvectis Pharma (NVCT) has 5 years of Treasury Shares data on file, last reported at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 36.55% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (up 36.55% YoY), and the FY2025 full-year result was $2.2 million, up 63.03% from the prior year.
• Treasury Shares climbed to $2.9 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $2.9 million in Q1 2026 to a low of $941496.0 in Q4 2023.
• A 4-year average of $1.9 million and a median of $2.1 million in 2025 frame the typical range for Treasury Shares.
• Across the five-year window, Treasury Shares surged 63.03% in 2025 and jumped 36.55% in 2026, its largest moves.
• Tracing NVCT's Treasury Shares over 4 years: stood at $941496.0 in 2023, then surged by 45.06% to $1.4 million in 2024, then surged by 63.03% to $2.2 million in 2025, then gained by 29.54% to $2.9 million in 2026.
• Business Quant data shows NVCT's Treasury Shares at $2.9 million in Q1 2026, $2.2 million in Q4 2025, and $2.2 million in Q3 2025.